Muscular dystrophy encompasses a collection of muscular conditions characterised by disruptions in the production of the essential dystrophin protein, critical for maintaining healthy muscle function. The development of abnormal gene mutations gives rise to muscle degeneration, resulting in a gradual weakening of the muscles and a subsequent rise in CPK levels. The initial symptoms typically manifest as muscle weakness and fatigue, which progressively evolve into muscle wasting and deformities. Over time, individuals affected by this condition often require assistance for mobility and walking.

One avenue explored in the pursuit of managing muscular dystrophy is stem cell therapy. Our focus lies on arresting or delaying the disease’s progression. Encouragingly, we have observed significant reductions in blood markers associated with the condition, indicating potential improvements in muscle health and overall well-being for affected individuals.